These positive outcomes are promising for individuals struggling with narcolepsy, as they provide hope for improved management of their condition. However, Harsh says oxybate therapy is not for everyone.
CCDC3 has shown to repress inflammatory activity of TNF-alpha, a cytokine postulated involved in sleep regulation and MARCHF1 has shown to inhibit cellular insulin sensitivity and promotes NF-KB, with degree of activation positively correlating with OSA severity.
Risk factors for trouble sleeping identified, including female sex, former smoking, and diabetes, obstructive lung disease, daytime sleepiness, insomnia, nocturia, and/or snorting/gasping/breathing cessation during sleep.
A preference for eveningness was significantly associated with worse overall sleep difficulties, longer sleep latency, reduced sleep satisfaction, more prolonged sleep inertia, more daytime naps, and more severe depressive symptomatology.